We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Senate Committee on Health, Education, Labor, & Pensions (HELP) is launching a probe of the compounding crisis, asking the Massachusetts pharmacy registrar to explain why New England Compounding Center (NECC) was allowed to operate as a large-scale drug manufacturer.
Read More
GlaxoSmithKline will soon give researchers access to detailed anonymized patient-level clinical data for approved drugs and dropped investigational products.
Read More
Hydrocodone-containing combination products, such as hydrocodone/acetaminophen (Vicodin), should be kept as Schedule III controlled substances and not be subject to tighter regulations to prevent abuse, the FDA said.
Read More
Generic-drug maker Mylan is on the prowl for acquisitions to bolster its product line and expand geographically, and would consider deals valued at “well over” $4 billion, the company’s leader said Thursday.
Read More
Boehringer Ingelheim Pharmaceuticals Inc agreed to pay $95 million to U.S. government agencies to settle civil allegations that it illegally marketed drugs for unapproved uses, the U.S. Justice Department said.
Read More
Redectane and Mesupron are now Wilex’s key products after the Rencarex Phase III ARISER data showed no efficacy; Rencarex has been discontinued.
Read More